AMGN

Amgen Inc.

Healthcare
328.26 -0.87 -0.26% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 177.16B
EV —
Shares Out 539.71M
Revenue (ttm) 37.22B
Net Income 7.80B
Beta —
P/E 22.73
Forward P/E —
EPS (ttm) $14.37
P/S 4.76
P/B 19.29
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 8.43%
ROE 93.87%
ROIC 13.64%
Gross Margin —
Oper. Margin 28.39%
Profit Margin 20.96%
Debt/Eq 6.24
LT Debt/Eq 84.95%
Quick Ratio —
Current Ratio 1.26
Book/sh 17.02
Cash/sh 22.29
Div Yield 2.99%
Div TTM $9.80
Payout Ratio 68.2%
SMA20 -1.31%
SMA50 -3.75%
SMA200 -0.11%
Volume 1,558,780
Avg Volume 2.70M
Rel Volume —
Perf Week -2.53%
Perf Month -0.40%
Perf Quarter -10.70%
Perf Half Y -0.49%
Perf YTD 0.29%
Perf Year 14.34%
Perf 3Y 47.94%
Perf 5Y 38.59%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $2.3800
TTM Yield 2.99%
TTM Amount $9.80
Payout Ratio 68.2%
3-Yr Growth (CAGR) 6.71%
5-Yr Growth (CAGR) 8.05%

Last 12 Payouts

Period Ex-Date Amount / Share
Q4 2025 ~2026-04-01 $2.3800
Q1 2026 ~2026-03-31 $2.5200
Q1 2025 ~2025-12-31 $2.5200
Q3 2025 ~2025-09-30 $2.3800
Q4 2024 ~2025-04-01 $2.2500
Q1 2025 ~2025-03-31 $2.3800
Q1 2024 ~2024-12-31 $2.3800
Q3 2024 ~2024-09-30 $2.2500
Q1 2024 ~2024-03-31 $2.2500
Q4 2023 ~2024-03-31 $2.1300
Q3 2023 ~2023-12-31 $2.2500
Q3 2023 ~2023-09-30 $2.1300

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Amgen Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics. For more than 45 years, Amgen's mission has been to serve patients by developing innovative and biosimilar medicines addressing serious illnesses and unmet medical needs of a rapidly aging global population. The company's business spans multiple therapeutic areas including General Medicine (cardiovascular and other conditions), Oncology, Rare Disease, and Inflammation. Amgen's product portfolio includes major brands such as Repatha, MariTide (maridebart cafraglutide), IMDELLTRA, LUMAKRAS, Vectibix, UPLIZNA, TEZSPIRE, TEPEZZA, BLINCYTO, Kyprolis, Aranesp, and Enbrel, among others. In 2025, the company delivered strong financial performance with 10% year-over-year revenue and sales growth, achieved record sales for 18 products, had 14 products exceeding $1 billion in sales, and received five FDA approvals. Amgen invests substantially in research and development, with $7 billion invested in R&D in 2025, and manufactures products across multiple facilities in the U.S. and internationally. The company serves patients globally through its innovative and biosimilar medicine portfolios.

Name
Amgen Inc.
Industry
Biotechnology
CEO
Robert A. Bradway · Chairman of the Board, Chief Executive Officer and President
Employees
—
IPO Date
2018-05-01
Phone
(805) 447-1000
Address
One Amgen Center Drive, Thousand Oaks, CA 91320-1799
Website
www.amgen.com

Key Executives

Name Title FY Pay
Brian J. Druker Director —
Michael V. Drake Director —
Wanda M. Austin Director —
Robert A. Eckert Lead Independent Director —
Robert A. Bradway Chairman of the Board, Chief Executive Officer and President —

Latest News